Common Contracts
6 similar Underwriting Agreement contracts by Acer Therapeutics Inc., Bridge Bancorp Inc, Clearside Biomedical, Inc., others
ACER THERAPEUTICS INC. UNDERWRITING AGREEMENT 2,222,222 Shares of Common Stock ($0.0001 Par Value)Underwriting Agreement • August 1st, 2018 • Acer Therapeutics Inc. • Pharmaceutical preparations • New York
Shares Clearside Biomedical, Inc. Common Stock ($0.001 Par Value) EQUITY UNDERWRITING AGREEMENTUnderwriting Agreement • May 11th, 2016 • Clearside Biomedical, Inc. • Pharmaceutical preparations • New York
Clearside Biomedical, Inc., a Delaware corporation (the “Issuer”), proposes to sell to the several underwriters (the “Underwriters”) named in Schedule I hereto for whom you are acting as representatives (the “Representatives”) an aggregate of shares of the Issuer’s Common Stock, $0.001 par value per share (the “Firm Securities”). The respective amounts of the Firm Securities to be so purchased by the several Underwriters are set forth opposite their names in Schedule I hereto. The Issuer also proposes to sell at the Underwriters’ option an aggregate of up to additional shares of the Issuer’s Common Stock (the “Option Securities”) solely to cover over-allotments, as set forth below.
•] Shares Trupanion, Inc. Common Stock ($0.00001 Par Value Per Share) UNDERWRITING AGREEMENT July , 2014Underwriting Agreement • July 7th, 2014 • Trupanion Inc. • Hospital & medical service plans • New York
Trupanion, Inc., a Delaware corporation (the “Issuer”), proposes to sell to the several underwriters (the “Underwriters”) named in Schedule I hereto for whom RBC Capital Markets, LLC, Barclays Capital Inc. and Stifel, Nicolaus & Company, Incorporated are acting as the representatives (“you” or the “Representatives”) an aggregate of [•] shares of the Issuer’s Common Stock, $0.00001 par value per share (the “Firm Securities”). The respective amounts of the Firm Securities to be so purchased by the several Underwriters are set forth opposite their names in Schedule I hereto. The Issuer also proposes to sell at the Underwriters’ option an aggregate of up to [•] additional shares of the Issuer’s Common Stock (the “Option Securities”), as set forth below.
1,675,000 Shares1 BRIDGE BANCORP, INC. Common Stock ($0.01 Par Value) UNDERWRITING AGREEMENTUnderwriting Agreement • October 3rd, 2013 • Bridge Bancorp Inc • National commercial banks • New York
As described in the Prospectus referred to below, the Issuer has entered into a definitive agreement, dated as of September 27, 2013 (the “Merger Agreement”) to acquire FNBNY Bancorp and its wholly owned subsidiary, the First National Bank of New York (collectively “FNBNY”). The consummation of the transactions contemplated by the Merger Agreement are to occur subsequent to the Closing Date (as defined below) and any Option Closing Date (as defined below).
] Shares Endocyte, Inc. Common Stock ($0.001 Par Value) UNDERWRITING AGREEMENTUnderwriting Agreement • July 21st, 2011 • Endocyte Inc • Pharmaceutical preparations • New York
Endocyte, Inc., a Delaware corporation (the “Issuer”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), and the stockholder of the Issuer (the “Selling Stockholder”) named in Schedule I hereto proposes to sell to the Underwriters for whom you are acting as representatives (the “Representatives”) an aggregate of 4,841,610 shares (the “Firm Securities”) of the Issuer’s common stock, par value $0.001 per share (the “Common Stock”) pursuant to this underwriting agreement (the “Agreement”), of which 4,000,000 shares are to be issued and sold by the Issuer (the “Issuer Securities”) and 841,610 shares are to be sold by the Selling Stockholder (the “Stockholder Securities”).
2,926,829 Shares1 CNB FINANCIAL CORPORATION Common Stock (No Par Value) UNDERWRITING AGREEMENTUnderwriting Agreement • June 15th, 2010 • CNB Financial Corp/Pa • State commercial banks • New York
CNB Financial Corporation, a Pennsylvania corporation (the “Issuer”), proposes to sell to the several underwriters (the “Underwriters”) named in Schedule I hereto for whom you are acting as Representative (the “Representative”) an aggregate of 2,926,829 shares of the Issuer’s Common Stock, no par value (the “Firm Shares”). The respective amounts of the Firm Shares to be so purchased by the several Underwriters are set forth opposite their names in Schedule I hereto. The Issuer also proposes to sell, at the Underwriters’ option, an aggregate of up to 439,024 additional shares of the Issuer’s Common Stock (the “Option Shares”) as set forth below.
